GFM
LGND icon

GF Fund Management’s Ligand Pharmaceuticals LGND Stock Holding History

GF Fund Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Sell
425
-18
-4% -$4.24K ﹤0.01% 304
2026
Q1 		$88.4K Buy
443
+57
+15% +$11.3K ﹤0.01% 349
2025
Q4 		$73K Sell
386
-36
-9% -$6.92K ﹤0.01% 372
2025
Q3 		$74.8K Sell
422
-62
-13% -$9.22K ﹤0.01% 358
2025
Q2 		$55K Hold
484
– – ﹤0.01% 406
2025
Q1 		$50.9K Buy
484
+87
+22% +$9.84K ﹤0.01% 418
2024
Q4 		$42.5K Buy
+397
New +$44.9K ﹤0.01% 403

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's LGND Position: Q2 2026 in Review

GF Fund Management reduced its Ligand Pharmaceuticals (LGND) stake by 4.1% in Q2 2026, selling an estimated $4.24K and leaving 425 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #304.

GF Fund Management first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • GF Fund Management held 425 shares of Ligand Pharmaceuticals worth $134K as of Q2 2026.
  • GF Fund Management sold 18 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.24K.
  • Ligand Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #304 holding.
  • GF Fund Management first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.